What Is Recent in Pancreatic Cancer Immunotherapy?

被引：20

作者：

Niccolai, Elena ^{[1
,2
]}

Prisco, Domenico ^{[2
,3
]}

D'Elios, Mario Milco ^{[1
,2
,4
]}

Amedei, Amedeo ^{[1
,2
,4
,5
]}

机构：

[1] Univ Florence, Dept Internal Med, I-50134 Florence, Italy

[2] Azienda Osped Univ Careggi, Dept Biomed, Patol Med Unit, I-50134 Florence, Italy

[3] Univ Florence, Dept Med & Surg Crit Care, I-50134 Florence, Italy

[4] Univ Florence, Ctr Oncol Minimally Invas Surg, I-50134 Florence, Italy

[5] Univ Florence, Dept Internal Med, Div Immunol, I-50134 Florence, Italy

来源：

BIOMED RESEARCH INTERNATIONAL | 2013年 / 2013卷

关键词：

GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; PULSED DENDRITIC CELLS; PERSONALIZED PEPTIDE VACCINATION; HUMAN MONOCLONAL-ANTIBODY; TUMOR-ASSOCIATED ANTIGEN; PHASE-III TRIAL; GM-CSF GENE; TELOMERASE ACTIVITY; IN-VITRO;

D O I：

10.1155/2013/492372

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Pancreatic cancer (PC) represents an unresolved therapeutic challenge, due to the poor prognosis and the reduced response to currently available treatments. Pancreatic cancer is the most lethal type of digestive cancers, with a median survival of 4-6 months. Only a small proportion of PC patients is curative by surgical resection, whilst standard chemotherapy for patients in advanced disease generates only modest effects with considerable toxic damages. Thus, new therapeutic approaches, specially specific treatments such as immunotherapy, are needed. In this paper we analyze recent preclinical and clinical efforts towards immunotherapy of pancreatic cancer, including passive and active immunotherapy approaches, designed to target pancreatic-cancer-associated antigens and to elicit an antitumor response in vivo.

引用

页数：14

共 154 条

[91] Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines [J].

Melief, Cornelis J. M. ;

van der Burg, Sjoerd H. .

NATURE REVIEWS CANCER, 2008, 8 (05) :351-360

[92] Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer [J].

Miyazawa, Motoki ;

Ohsawa, Ryuji ;

Tsunoda, Takuya ;

Hirono, Seiko ;

Kawai, Manabu ;

Tani, Masaji ;

Nakamura, Yusuke ;

Yamaue, Hiroki .

CANCER SCIENCE, 2010, 101 (02) :433-439

[93] Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives [J].

Mocellin, S. ;

Pilati, P. ;

Nitti, D. .

CURRENT MEDICINAL CHEMISTRY, 2009, 16 (36) :4779-4796

[94] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

[95] The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer [J].

Morse, MA ;

Nair, SK ;

Boczkowski, D ;

Tyler, D ;

Hurwitz, HI ;

Proia, A ;

Clay, TM ;

Schlom, J ;

Gilboa, E ;

Lyerly, HK .

JOURNAL OF GASTROINTESTINAL CANCER, 2002, 32 (01) :1-6

[96] Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred [J].

Mukherjee, P ;

Ginardi, AR ;

Madsen, CS ;

Sterner, CJ ;

Adriance, MC ;

Tevethia, MJ ;

Gendler, SJ .

JOURNAL OF IMMUNOLOGY, 2000, 165 (06) :3451-3460

[97] Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutation [J].

Myung, SJ ;

Kim, MH ;

Kim, YS ;

Kim, HJ ;

Park, ET ;

Yoo, KS ;

Lim, BC ;

Seo, DW ;

Lee, SK ;

Min, YI ;

Kim, JY .

GASTROINTESTINAL ENDOSCOPY, 2000, 51 (06) :708-713

[98] Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA [J].

Nair, SK ;

Boczkowski, D ;

Morse, M ;

Cumming, RI ;

Lyerly, HK ;

Gilboa, E .

NATURE BIOTECHNOLOGY, 1998, 16 (04) :364-369

[99] Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [J].

Nestle, FO ;

Alijagic, S ;

Gilliet, M ;

Sun, YS ;

Grabbe, S ;

Dummer, R ;

Burg, G ;

Schadendorf, D .

NATURE MEDICINE, 1998, 4 (03) :328-332

[100]

Ng SSW, 2002, MOL CANCER THER, V1, P777

← 5 6 7 8 9 10 11 12 13 14 →